155 related articles for article (PubMed ID: 17634535)
1. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.
Landen CN; Lin YG; Immaneni A; Deavers MT; Merritt WM; Spannuth WA; Bodurka DC; Gershenson DM; Brinkley WR; Sood AK
Clin Cancer Res; 2007 Jul; 13(14):4098-104. PubMed ID: 17634535
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy.
Lassmann S; Shen Y; Jütting U; Wiehle P; Walch A; Gitsch G; Hasenburg A; Werner M
Clin Cancer Res; 2007 Jul; 13(14):4083-91. PubMed ID: 17634533
[TBL] [Abstract][Full Text] [Related]
3. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S
J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448
[TBL] [Abstract][Full Text] [Related]
4. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
Lassus H; Staff S; Leminen A; Isola J; Butzow R
Gynecol Oncol; 2011 Jan; 120(1):11-7. PubMed ID: 20937525
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
7. Aurora kinases as prognostic biomarkers in ovarian carcinoma.
Mendiola M; Barriuso J; Mariño-Enríquez A; Redondo A; Domínguez-Cáceres A; Hernández-Cortés G; Pérez-Fernández E; Sánchez-Navarro I; Vara JA; Suárez A; Espinosa E; González-Barón M; Palacios J; Hardisson D
Hum Pathol; 2009 May; 40(5):631-8. PubMed ID: 19157502
[TBL] [Abstract][Full Text] [Related]
8. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
9. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
10. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer.
Gritsko TM; Coppola D; Paciga JE; Yang L; Sun M; Shelley SA; Fiorica JV; Nicosia SV; Cheng JQ
Clin Cancer Res; 2003 Apr; 9(4):1420-6. PubMed ID: 12684414
[TBL] [Abstract][Full Text] [Related]
11. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
12. [Aurora-a is a predictive marker for stage III epithelial ovarian cancers].
Lassmann S; Shen Y; Jütting U; Whiele P; Walch A; Gitsch G; Hasenburg A; Werner M
Verh Dtsch Ges Pathol; 2007; 91():225-32. PubMed ID: 18314619
[TBL] [Abstract][Full Text] [Related]
13. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
14. Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990.
Venesmaa P
Obstet Gynecol; 1994 Jul; 84(1):8-11. PubMed ID: 8008329
[TBL] [Abstract][Full Text] [Related]
15. [Impacts of chemotherapy on long-term survival of patients with advanced epithelial ovarian cancer].
Zang R; Cai S; Zhang Z
Zhonghua Fu Chan Ke Za Zhi; 2001 Dec; 36(12):738-41. PubMed ID: 16136895
[TBL] [Abstract][Full Text] [Related]
16. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
17. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR
Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients.
Chen YJ; Chen CM; Twu NF; Yen MS; Lai CR; Wu HH; Wang PH; Yuan CC
Virchows Arch; 2009 Nov; 455(5):431-40. PubMed ID: 19838728
[TBL] [Abstract][Full Text] [Related]
19. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
20. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma.
Kulkarni AA; Kingsbury SR; Tudzarova S; Hong HK; Loddo M; Rashid M; Rodriguez-Acebes S; Prevost AT; Ledermann JA; Stoeber K; Williams GH
Clin Cancer Res; 2009 Apr; 15(7):2417-25. PubMed ID: 19318489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
